mirror-images Oppenheimer has initiated coverage of Y-mAbs Therapeutics ( NASDAQ: YMAB ) off at outperform highlighting the biotech's SADA platform, calling it "the most advanced pre-targeting platform currently in development for delivery of targeted radiopharmaceutical therapies." The investment bank has a price target of $23 (~106% upside.
Back to Health Page
